UNSPSC 51313431: Doxylamine succinate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9BI9B5YI2, chemically known as succinic acid, compd. with 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine (1:1) (8ci) but more generally known as doxylamine hydrogen succinate, which bears US NIH Compound Identifier 11224.

UNSPSC 51313431 Doxylamine succinate is a Commodity code that covers the procurement of pharmaceutical active ingredients and finished dosage forms, though recent state and local solicitation activity shows little direct demand for doxylamine specifically. The three most recent opportunities tagged under this code involve broader pharmaceutical and naloxone procurement rather than sleep-aid or antihistamine products: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health initiatives; the Texas Health and Human Services Commission is conducting market research on direct-to-manufacturer prescription delivery models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is sourcing generic multi-source pharmaceuticals and OTC products across multiple participating states. Issuing bodies range from county health departments to state agencies and cooperative purchasing consortia, reflecting fragmented demand across different procurement vehicles and policy objectives. The code shows limited standardization in what is actually being bought — solicitations under it span emergency medical supplies, pharmaceutical benefit program innovations, and wholesale generic drug sourcing, suggesting that state and local procurement offices may be applying this code inconsistently or that doxylamine itself sees minimal recent competitive solicitation activity.

Geographic activity is concentrated in the South and upper Midwest, with posted opportunities in Florida, Texas, and Minnesota as of early 2026. The most recent solicitation is Seminole County's IFB 60459723LAS, posted June 30, 2026, for 1,900 units of naloxone annually with quarterly deliveries due by July 26, 2026 (note: the solicitation contains an inconsistent date of July 26, 2023). MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products closed March 26, 2026, with evaluation weighted heavily on price competitiveness (75 percent) and requiring compliance with cGMP, Drug Supply Chain Security Act certification, and relationships with authorized wholesalers. The Texas HHS RFI HHS0017013 was exploratory market research posted April 3, 2026, rather than a formal competitive solicitation. Vendors pursuing this code should note that recent opportunities emphasize wholesale distribution relationships, FDA compliance, and specific insurance and bonding requirements, and that the code's application to doxylamine-specific products appears limited in current state and local contracting activity.